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Background. Retinoic acid (RA), the bioactive derivative of Vitamin A, by epigenetically controlling transcription through the
RA-receptors (RARs), exerts a potent antiproliferative effect on human cells. However, a number of studies show that RA can
also promote cell survival and growth. In the course of one of our studies we observed that disruption of RA-receptor alpha,
RARa, abrogates the RA-mediated growth-inhibitory effects and unmasks the growth-promoting face of RA (Ren et al., Mol.
Cell. Biol., 2005, 25:10591). The objective of this study was to investigate whether RA can differentially govern cell growth, in
the presence and absence of RARa, through differential regulation of the ‘‘rheostat’’ comprising ceramide (CER), the
sphingolipid with growth-inhibitory activity, and sphingosine-1-phosphate (S1P), the sphingolipid with prosurvival activity.
Methodology/Principal Findings. We found that functional inhibition of endogenous RARa in breast cancer cells by using
either RARa specific antagonists or a dominant negative RARa mutant hampers on one hand the RA-induced upregulation of
neutral sphingomyelinase (nSMase)-mediated CER synthesis, and on the other hand the RA-induced downregulation of
sphingosine kinase 1, SK1, pivotal for S1P synthesis. In association with RA inability to regulate the sphingolipid rheostat, cells
not only survive, but also grow more in response to RA both in vitro and in vivo. By combining genetic, pharmacological and
biochemical approaches, we mechanistically demonstrated that RA-induced growth is, at least in part, due to non-RAR-
mediated activation of the SK1-S1P signaling. Conclusions/Significance. In the presence of functional RARa, RA inhibits cell
growth by concertedly, and inversely, modulating the CER and S1P synthetic pathways. In the absence of a functional RARa,
RA–in a non-RAR-mediated fashion–promotes cell growth by activating the prosurvival S1P signaling. These two distinct, yet
integrated processes apparently concur to the growth-promoter effects of RA.
Citation: Somenzi G, Sala G, Rossetti S, Ren MQ, Ghidoni R, et al (2007) Disruption of Retinoic Acid Receptor Alpha Reveals the Growth Promoter Face
of Retinoic Acid. PLoS ONE 2(9): e836. doi:10.1371/journal.pone.0000836
INTRODUCTION
Retinoic acid (RA), the bioactive derivative of dietary Vitamin A
and beta-carotene, is a powerful signaling molecule controlling cell
proliferation [1]. Normally, RA exerts an inhibitory action on cell
proliferation via specialized transcription factors, the nuclear RA
receptors, RARs [2]. Cells evolved an amazing apparatus to safely
control the RA antiproliferative action. First, cells finely regulate
the level of intracellular RA through a sophisticated metabolic/
homeostatic process [3]; second, they use specialized cellular
retinoic acid binding proteins (CRABPs) to chaperone RA from
the cytoplasm directly onto the RARs in the nucleus [4]; third,
they have evolved a two-tier RAR-regulated system to control the
downstream transcription of genes in response to RA [5]. RA,
after binding the nuclear receptor RARa, triggers the transcription
of other downstream RARs, including the RA-receptor and tumor
suppressor, RARb2 [6]. RARb2 autoregulates its own transcription
and, in turn, the transcription of a multitude of downstream RA-
responsive target genes [7,8].
Heterogeneous factors can lead to functional inhibition of RA-
RARa signaling. These factors include non-random genetic
mutations producing chimeric RARa receptors with dominant
negative function, such as the leukemia-associated PML-RARa
and PLZF-RARa [9 and references within], RARa epigenetic
silencing in epithelial cancer cells [10–13], and a defective
intracellular level of RA consequent to defects of the retinol/RA
metabolism/homeostasis [4,14–17].
According to several literature reports, RA and its dietary
precursors can also promote, rather than inhibit, cell survival and
growth [18–22]. In the course of a recent study, we observed that
disruption of RARa signaling in RA-sensitive breast cells not only
leads to RA-resistance, but unexpectedly unmasks the growth-
promoter face of RA [13,23–25].
Here we show that in RA-sensitive cells with a functional RARa
signaling RA leads to growth inhibition consequent to the
concerted upregulation of neutral sphingomyelinase (nSMase),
one of the enzymes leading to the synthesis of the antiprolifera-
tive/propaptotic ceramide (CER), and downregulation of sphin-
gosine kinase 1 (SK1), the enzyme leading to the synthesis of the
prosurvival sphingosine-1-phosphate (S1P). In contrast, disruption
of RARa signaling in the same cells results, in response to RA, into
increased proliferation associated with both loss of concerted
regulation of nSMase and SK1, and induction of intracellular S1P.
Altogether our findings indicate that the presence of RARa is
essential for the proper regulation of the sphingolipid rheostat by
RA. In the absence of RARa, RA no longer executes its growth-
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inhibitory action through its canonical receptors, but activates the
prosurvival SK1-S1P pathway through alternate non-RAR
receptor(s).
RESULTS
Cells with a functionally disrupted RARa signaling
become both RA-resistant and susceptible to
RA-induced cell growth in vitro and in vivo
By using different strategies to functionally inhibit RA-RARa
signaling in RA-sensitive breast cancer cells (T47D), we found
that–concomitant with heritable epigenetic gene silencing of the
downstream RARb2 receptor and tumor suppressor–cells not only
survive, but also proliferate significantly more in response to RA
([13] and Fig. 1A). Specifically, we observed that T47D-derived
clones, obtained by stably inhibiting the endogenous RARa
signaling with either the RARa-specific antagonist ER50891 (here
shown a prototypic clone, ER-C4) (Fig. 1B, top) or the dominant
negative DN RARa403 mutant (here shown a prototypic clone,
DNC8) (Fig.1B, bottom), were not only RA-resistant, but grew
significantly more in the presence of RA (1 mM, 72 h) as shown by
both colony formation assay and cell proliferation assay, while
their respective controls, T47D in the case of ER-C4, and LXC5
in the case of DNC8, were growth-inhibited by RA. We will
present hereafter only the results concerning the LXC5/DNC8
isogenic model, because the T47D/ER-C4 show an identical RA-
response for the different parameters that we analyzed in this
study.
The increased RA-induced growth is supported by the
observation that cells in the presence of RA (1 mM, 72 h)
transition more rapidly from the G1 to the S phase (Fig. 1C, left)
in agreement with an increased transcription of the cyclin D1
gene, encoding a protein pivotal for the G1-S phase transition
(Fig.1C, right).
RA, and its dietary precursor retinol, can apparently promote
DNC8 cell growth in vivo. DNC8 cells xenografted subcutaneously,
and bilaterally, in the dorsal flank of female nude mice (see
experimental scheme, Fig. 2A), were clearly growth-promoted by
chronic RA treatment (2.5 mg/kg) delivered by daily intraperito-
neal injection. Weekly assessment of tumor size showed that RA
clearly promoted the growth of DNC8 xenograft tumors up to the
sixth week (Fig. 2B, right); thereafter tumors stop growing (data
not shown). In contrast, the same RA treatment induced growth
inhibition of the control LXC5 xenograft tumors (Fig. 2B, left).
Immunocytochemistry of DNC8 tumor sections after six-week
RA-treatment showed a significantly (p,0.05) higher number of
cells positive for the proliferation marker Ki67 (Fig. 2C, left).
Significantly (p,0.01) higher was also the level of cyclin D1
transcription (Fig. 2C, right).
Based on the overall in vitro and in vivo observations, we
hypothesized that two distinct effects occur as a consequence of
disruption of RARa function. The first effect is the abrogation of
growth inhibition mediated by RA through RARa, and the second
effect is a non-RARa-mediated stimulation of cell growth by RA
itself. To identify these effects we focused our analysis on CER and
S1P signaling, two sphingolipid signaling pathways exerting
opposite action on cell growth.
RA fails to induce CER synthesis in cells with
functional RARa inhibition
The metabolism of both CER and S1P is tightly integrated
(Fig. 3A). CER can be generated either as a result of
sphingomyelin hydrolysis, catalyzed by either one of two
sphingomyelinases, the neutral sphingomyelinase (nSMase) and
the acid sphingomyelinase (aSMase), or by de novo synthesis as
a result of condensation of L-serine and palmitoyl CoA catalyzed
by serine palmitoyltransferase (SPT) (Fig. 3A). In preliminary cell
labeling experiments of T47D cells with either [3H] sphingosine or
[3H] palmitate, it was apparent that RA induces CER synthesis via
sphingomyelin hydrolysis, and not de novo synthesis in cells with
a functional RARa (Fig. 3B). Consistently, both the transcription
level of the two SPT subunits genes, LCB1 and LCB2, and the SPT
activity did not vary significantly between LXC5 and DNC8 cells
in response to RA (Fig. 3C, top). In contrast, both the transcription
level and activity of one of the sphingomyelinases, nSMase (Fig. 3C
middle), significantly (p,0.01) increased in response to RA in
LXC5, but not in DNC8 cells. Conversely, the transcription and
activity of aSMase remained unchanged (Fig. 3C bottom).
Moreover, a specific nSMase inhibitor, GW4869 [26] (5 mM,
48 h) significantly (p,0.05) counteracted RA-induced growth
inhibition (Fig. 3D, left) as well as RA-induced CER level in LXC5
cells (Fig. 3D, right).
To validate independently whether nSMase-driven CER
synthesis is under RARa regulation, we used two specific RARa
antagonists RO415253 [27] and ER50891 [28]. Both antagonists
effectively inhibit RA action at RARa, since they abrogate RA-
induced transcriptional upregulation of RARb2, a prototypic
direct RARa-target (Fig. 4C). Treatment of T47D cells with a 100-
fold concentration of either one of the RARa antagonists relative
to RA for 72 h, counteracted both the RA-induced antiprolifera-
tive activity (Fig. 4A) and the RA-induced CER synthesis in T47D
cells (Fig. 4B). Further, both RARa antagonists inhibited the RA-
induced transcriptional upregulation of nSMase (Fig. 4C). These
findings demonstrate a functional interference of both antagonists
with RA-induced, nSMase-mediated CER synthesis.
Thus, by using two independent approaches, we clearly
demonstrated that disruption of RARa function abrogates the
nSMase-mediated synthesis of CER in response to RA.
Fenretinide, a retinoid that works in an
RAR-independent fashion, can induce CER in cells
with functional RARa inhibition
Fenretinide (4-HPR) is a synthetic retinoid that was shown to be
effective for prevention and treatment of breast cancer [29,30].
Fenretinide was reported to induce CER accumulation in a non-
RAR-dependent fashion [31,32]. Consistently, DNC8 cells, while
unable of nSMase-induced CER synthesis in response to RA
(1 mM, 72 h) (Fig. 5A left), were capable of accumulating CER in
response to fenretinide (4 mM, 72h) (Fig. 5A, right). Fenretinide-
induced CER accumulation is paralleled both by a consistent
antiproliferative (Fig. 5B, left) and proapoptotic effect (Fig. 5B,
right).
These observations support the conclusion that the inability of
RA to induce CER synthesis in cells with functional disruption of
RARa is due to lack of upregulation of the specific nSMase-
mediated CER synthetic pathway, and not to an overall failure of
the entire CER synthetic apparatus.
RA fails to downregulate both SK1 transcription and
activity in cells with functional RARa inhibition
The metabolism of the antiproliferative CER is intrinsically linked
to the metabolism of the prosurvival S1P effector (Fig. 3A). For this
reason, we measured the SK activity in LXC5 and DNC8 cells
both at baseline (in the absence of RA) and in the presence of RA.
Apparently, LXC5 cells have a significantly (p,0.01) lower level of
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Figure 1. Cells with a functionally disrupted RARa signaling become both RA-resistant and susceptible to RA-induced cell growth. A) Differential
response to RA according to the integrity of the RARa signaling. B) Both the ER-C4 clone, in which RA signaling was impaired by treatment with the
RARa antagonist ER50891 (top), and the DNC8 clone, expressing the dominant negative RARa403 (bottom), were growth-stimulated by RA as shown
by both colony formation assay and cell proliferation assay, while their cognate controls (T47D and LXC5, respectively) were growth inhibited. C) RA
expedites the G1-S transition in DNC8 cells (left), and significantly induces cyclin D1 transcription (right).
doi:10.1371/journal.pone.0000836.g001
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SK1 activity than DNC8 cells already at baseline (Fig. 6A). Further,
RA (1 mM, 72 h) can induce a significant downregulation (p,0.05)
of SK1 activity in LXC5 but not in DNC8 cells (Fig. 6A, upper
inserts). The SK1 activity pattern in LXC5 and DNC8, at baseline
and after RA-treatment, mirrors the transcription pattern of the SK1
gene, one of the two SK genes (Fig. 6B, top left). The transcription of
sphingosine kinase 2 (SK2), sphingosine-1-phosphate lyase (S1P lyase),
and sphingosine-1-phosphate phosphatase (S1PP) is not significantly
different in LXC5 and DNC8 cells both at baseline and after RA-
treatment (Fig. 6B, top right, and bottom).
Apparently, only in cells with a functional RARa, RA
transcriptionally regulates in an opposite fashion the metabolic
pathways leading to either CER or S1P synthesis, by upregulating
on one hand nSMase transcription and by downregulating on the
other hand SK1 transcription, thus synergistically inhibiting cell
proliferation.
Evidence that RA fails to regulate in an opposite
fashion CER synthesis and SK activity in cells lacking
endogenous RARa
Next, we searched for evidence that RA fails to regulate in an
opposite fashion CER synthesis and SK activity also in cells that
lack endogenous RARa function. For this reason, we chose a breast
cancer cell line, MDA-MB-231, that does not express endogenous
RARa (Fig 7A, left) and the other downstream RA-regulated RAR
genes, including RARb2 (Fig. 7A, right). MDA-MB-231 are
modestly, yet significantly (p,0.05) growth-promoted by RA
(Fig. 7B). Interestingly, in these cells RA fails to: induce nSMase
transcription (Fig. 7C, left), increase CER synthesis (Fig 7C,
middle), and downregulate both SK transcription and activity
(Fig. 7C, middle and right).
Treatment with the SK inhibitor 2-(p-hydroxyanilino)-4-(p-
chlorophenyl) thiazole (2 mM, 72 h) led to significant inhibition
(p,0.01) of MDA-MB-231 proliferation both in the absence and
presence of RA (Fig. 7D), indicating that RA-promoted cell
proliferation of MDA-MB-231 cells might be due, at least in part,
to activation of the SK1-S1P signaling pathway. In addition,
MDA-MB-231 can accumulate CER (Fig. 7E, left) and undergo
apoptosis (Fig. 7E, right) in response to fenretinide, showing that
other non-RAR-regulated ceramide synthetic pathways are still
functional. Thus, in different cell contexts, both when we disrupted
functional RARa (DNC8) or there is no endogenous RARa
(MDA-MB-231) it is apparent that the CER/S1P rheostat is not
regulated by RA as it does in cells with an intact RARa. In
contrast, RA seems to activate, rather than downregulate, the SK
signaling.
SK1-S1P signaling: a candidate growth promoting
mechanism of non-RAR-mediated RA action
RA-induced cell survival and growth have been documented in
different cells and tissues [33–35]. RA-induced proliferation in the
absence of a functional RARa signaling is not breast cancer cell
context-specific and can occur both in transformed and un-
transformed cells (unpublished observations). Apparently, a few
non-RAR targets can mediate RA-action [34,36,37]. We gathered
preliminary evidence that in DNC8 cells the RA non-RAR-
Figure 2. RA promotes tumor growth in vivo. A) LXC5 and DNC8 cells were xenografted in nude mice, which were treated with RA according to the
experimental scheme. B) Weekly assessment of tumor size over six weeks showed that DNC8 xenograft tumors of mice that received RA treatment
grew significantly more than tumors of mice that did not received RA treatment (right). LXC5 xenograft tumors underwent growth inhibition in
response to RA (left). C) RA significantly promoted cell proliferation as demonstrated by a significantly higher number of Ki67-positive cells (left) and
increased cyclin D1 transcription (right) in RA-treated DNC8 cells.
doi:10.1371/journal.pone.0000836.g002
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mediated proliferation effect is due, at least in part, to activation of
the SK1-S1P signaling pathway because of the following
observations. First, in the presence of RA, cyclin D1 transcription
is upregulated in DNC8 cells transfected with wild-type SK1
(Fig. 8A, left). Second, exogenous expression of a dominant
negative SK1 mutant (DNSK) in DNC8 cells significantly
(p,0.05) reduced the level of cyclin D1 transcription compared
to the level of cyclin D1 transcription in cells transfected with the
cognate empty vector (Fig. 8A, right). Third, treatment with the
specific SK inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thi-
azole, (2 mM, 72 h), led to significant inhibition (p,0.01) of DNC8
proliferation both in the absence, and presence of RA (Fig. 8B) as
it did in MDA-MB-231 cells (Fig. 7). Finally, by labeling
experiment with [3-3H] D-erythro-sphingosine, we observed
a significant (p,0.05) increase of intracellular S1P in DNC8 cells
in response to RA (1 mM, 72 h) (Fig. 8C).
We conclude that when RA is not channeled through RARa
there is no longer concerted transcriptional upregulation of
nSMase-mediated CER and transcriptional downregulation of
SK1 activity. In contrast, RA, through alternate, non-RAR
Figure 3. RA fails to induce nSMase-mediated CER synthesis in cells with functional RARa inhibition. A) Scheme showing the metabolic pathways
leading to the synthesis of both CER and S1P, two bioactive sphingolipids known for exerting opposite effects on proliferation. B) [3H] palmitate or
[3H] sphingosine labelling, in the presence and absence of RA, showing that RA induces CER accumulation through a sphingomyelinase pathway
(fluorographic pattern of CER and sphingomyelin (SM), respectively, in the upper inserts). C) Quantitative analysis of transcription and activity for the
different enzymes leading to CER synthesis in both LXC5 cells and DNC8 cells clearly indicates that RA induces CER through the nSMase pathway
(middle) and not the SPT (top) and aSMase (bottom) pathways. D) The nSMase inhibitor GW4869 significantly counteracted both RA-induced growth
inhibition (left) and CER accumulation (right).
doi:10.1371/journal.pone.0000836.g003
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target(s), manages to activate the SK1-S1P signaling, thus
promoting cell survival and growth (Fig. 8D).
DISCUSSION
In this study we provide mechanistic evidence that RA can act as
a growth inhibitor or a growth promoter according to the
functional status of RARa. Moreover, we provide evidence that in
the presence of a functional RARa, RA inhibits cell growth by
concertedly, and inversely, regulating the synthesis of two
bioactive sphingolipids, CER and S1P. In contrast, we show that
in the absence of RARa, RA, in a non-RAR-mediated fashion,
promotes cell growth by activating the SK1-S1P-signaling.
Specifically, we found that RA, when channeled through RARa
in RA-sensitive cancer cells, concertedly upregulates on one hand
nSMase, thus leading to accumulation of CER, the antiprolifera-
tive and proapoptotic sphingolipid, and on the other hand
downregulates SK1, pivotal for the synthesis of the oncogenic
S1P, the prosurvival sphingolipid. This regulation is lost in cells
(T47D) where we stably inhibited RARa function with either
a RARa antagonist, or a dominant negative RARa mutant and in
cells (MDA-MB-231) that lack endogenous RARa function.
Lack of RA-RARa-mediated control of the sphingolipid
rheostat explains why cells survive in the presence of RA.
However, we found that cells not only survive, but actually grow
more in the presence of RA. Thus, RA exerts a distinct effect that
is non-RAR-mediated because lack of RARa determines the
downregulation/silencing of the other two RARs, RARb and
RARc (data not shown). The growth-promoting action of RA and
its dietary precursors has puzzled investigators for many years.
Beta-carotene was shown to increase, rather than reduce, the
incidence of lung cancer [19,22] and head and neck cancer [36].
Both retinol and RA were shown to promote tumor growth in
transgenic models of both breast and colon cancer [18,21,35].
Here we show that chronic treatment with RA stimulates the
growth of cells with an impaired RARa function not only in vitro
but also in vivo. Thus, RA-induced expansion of cells may represent
a discrete step of the tumor progression process once cells have lost
RAR function. In the absence of functional RARs, RA apparently
activates, through non-RAR targets, one or more pro-proliferative
mechanisms. We provide evidence that one of these mechanisms is
the SK1-S1P signaling. We do not know yet through which
alternate, non-RAR target RA accomplishes to activate the SK1-
Figure 4. RARa antagonists counteract both RA-induced growth inhibition and nSMase-mediated CER synthesis. A) RO415253 (RO) (left) and
ER50891 (ER) (right) rescued T47D cells from RA-induced growth-inhibition. B) Both RO and ER counteracted the RA-induced CER synthesis. C) Both
RO and ER significantly counteracted the transcription of nSMase as well as the transcription of the control downstream RARa direct target RARb2.
doi:10.1371/journal.pone.0000836.g004
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S1P signaling. A potential non-RAR candidate target is protein
kinase alpha (PKCa). PKCa can physically bind RA [37], can
activate the SK signaling [38], and promote cell growth and tumor
progression [39]. Another non-RAR candidate target is PPARb/
d, an orphan nuclear receptor that binds with high affinity RA,
recently implicated in RA-induced survival [35]. PKCa and
PPARb/d are both expressed in our cell model with functionally
disrupted RARa (data not shown).
Our study indicates that drugs such as fenretinide that can
increase CER through pathways different from the RA-RARa-
regulated nSMase pathway, or SK inhibitors can overcome the
biological sequelae associated with the loss of RARa function and
counteract RA-induced growth by targeting the sphingolipid
rheostat. The identification of both non-RAR targets and mech-
anisms implicated in RA-mediated prosurvival/proliferation effects
might bring us a step closer to the solution of the RA-paradox.
MATERIALS AND METHODS
Cell cultures and biological assays
The T47D breast cancer cell line (ATCC, Manassas, VA) was
cultured in DMEM medium (Invitrogen, Carlsbad, CA) plus 5%
charcoal-dextran-stripped fetal bovine serum (Hyclone, Logan,
UT). The T47D-derived clones, DNC8 and LXC5, carrying
either a retroviral vector containing the human dominant-negative
RARa403 mutant [40], or the cognate empty vector were
developed as previously described [13]. The T47D-derived clone
ER-C4 was developed by isolating and expanding single colonies
that grew after treatment with RA 1 mM in combination with the
RARa antagonist ER50891 as previously described [13]. Treat-
ment with all-trans retinoic acid (RA) (Sigma, St Louis, MI), N-(4-
hydroxyphenyl) retinamide (4-HPR) (Sigma), the RARa antago-
nists ER50891 (provided by Dr. Kouichi Kikuchi, Discovery
Research Laboratories, Ibaraki, Japan) and RO415253 (provided
by Dr. Salvatore Toma, Genoa, Italy), the sphingosine kinase
inhibitor, 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole (Cal-
biochem, San Diego, CA), and the neutral sphingomyelinase
inhibitor (GW4869) (Sigma) are described in detail in the Results.
Cell proliferation was evaluated by either the 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [41] or the
Figure 5. Fenretinide can induce CER also in cells without a functional
RARa. A) DGK analysis of CER (autoradiography of CER species in the
upper inserts) showing that RA induces CER only in cells with
a functional RARa signaling (left), while fenretinide, a retinoid whose
action is RAR-independent, can induce CER also in cells without
a functional RARa signaling (right). B) Fenretinide-induced CER
accumulation has an antiproliferative and proapoptotic effect, as
shown by cell proliferation assay (left) and the presence of cleaved
PARP (right), respectively.
doi:10.1371/journal.pone.0000836.g005
Figure 6. RA fails to downregulate both SK1 transcription and activity in cells with functional RARa inhibition. A) Downregulation of SK1 activity
(S1P spots in the upper insert) in response to RA occurs in LXC5 cells but not DNC8 cells. B) SK1 transcription (but not the transcription of SK2, S1PP,
S1P lyase) is downregulated in response to RA in LXC5 cells but not in DNC8 cells.
doi:10.1371/journal.pone.0000836.g006
Retinoic Acid and Cell Growth
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Live/Dead Cell Viability assay (Invitrogen). For the colony
formation assay, exponentially growing cells were seeded at
56102 cells/well in 6-well plates in triplicate and allowed to
attach to the substrate. Cells were treated with or without RA
1 mM for 24 hours, and then the medium was replaced with drug-
free medium and the cells grown for 14–21 days. Colonies were
fixed with methanol and stained with Giemsa (Sigma). The total
area of the colonies was assessed by using Image J (NIH). For flow
cytometric cell cycle analysis, cells were trypsinized, washed with
cold phosphate buffered saline (PBS), fixed in 70% ethanol at 4uC
for 30 minutes, washed with cold 0.5% bovine serum albumin
(BSA), resuspended in 1 ml Krishan Buffer containing 0.1%
sodium citrate, 0.02 mg/ml RNase A (Qiagen, Valencia, CA),
0.20% NP40 (Sigma), 0.05 mg/ml propidium iodide (Sigma), kept
at 4uC for 30 minutes, and analyzed with a Fluorescence-
Activated Cell Sorter (FACS) (Becton Dickinson Biosciences,
San Jose, CA) equipped with Cellquest software. The data were
analyzed with ModFit LT software (Verity Software House, Inc.
Topsham, ME). Transient transfection was performed by
transfecting 56105 cells attached to the plastic substrate with
Figure 7. Evidence that RA fails to regulate in an opposite fashion CER synthesis and SK activity in cells lacking endogenous RARa. A) Lack of
endogenous RARa signaling (left) is demonstrated by lack of RA-induced transcription of the RARa target RARb2 (right). B) MDA-MB-231 are modestly,
but significantly, growth-promoted by RA. C) RA fails to induce nSMase transcription (left), CER synthesis (middle), SK1 transcription downregulation
(middle), and decrease of SK activity (right) in MDA-MB-231 cells. D) RA-induced MDA-MB-231 proliferation is significantly decreased by treatment
with a SK inhibitor. E) Fenretinide can effectively induce both CER synthesis (left) and apoptosis (right) in MDA-MB-231 cells.
doi:10.1371/journal.pone.0000836.g007
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either a vector carrying the dominant negative SK1 (pcDNA3-
hSKG82D) (provided by Dr. Stuart M. Pitson, Hanson Institute,
Adelaide, Australia) [42], or the cognate empty vector (pcDNA3,
Invitrogen), using LipofectAmine Plus (Invitrogen).
Animal studies and tumor analysis
Female athymic NCr-nu/nu mice (6–8 weeks old) were bought
from NCI-Frederick Animal Production Program (NCI, Frederick,
MD). All mice were kept in a temperature-controlled room on
Figure 8. SK1-S1P signaling: a candidate growth promoting mechanism of non-RAR-mediated RA action. A) Transient exogenous expression of
SK1 in DNC8 cells leads to upregulation of cyclin D1 transcription relative to cells expressing the cognate empty vector (left). Conversely, transient
exogenous expression of a dominant negative SK mutant in DNC8 cells negatively affects RA-induced cyclin D1 transcription (right). B) RA-induced
DNC8 proliferation is significantly decreased by treatment with a SK inhibitor. C) RA upregulates the S1P level (spots in the upper insert) in DNC8 cells.
D) Scheme showing that RA action mediated through RARa results in upregulation of nSMase-generated CER sythesis, concomitant with
downregulation of SK1 transcription/activity. These concerted antiproliferative metabolic changes concur to inhibit cell proliferation. Consequent to
an impaired RA-RARa signaling, these concerted antiproliferative metabolic changes do not occur, thus cells survive in the presence of RA. Moreover,
RA, through alternate, non-RAR (genomic or non-genomic) target(s), activates pro-survival signaling pathways, including the SK signaling pathway,
thus leading to the expansion of the RA-resistant cell pool.
doi:10.1371/journal.pone.0000836.g008
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a 12/12-h light/dark schedule, with food and water ad libitum.
Mice were estrogenized by intramuscular injection of Depo-
estradiol (Florida Infusion Co, Palm Harbor, FL) at 1.5 mg/kg
body weight. Two days after, mice were subcutaneously inoculated
in the flank region (bilaterally) with either 56106 DNC8 cells (16
mice) or 56106 LXC5 cells (16 mice) in 0.2 ml of a mixture of
serum-free DMEM (Invitrogen) and Matrigel (BD Biosciences,
Bedford, MA) (1:1, by vol). Mice inoculated with either LXC5 or
DNC8 cells were randomly divided into two groups of 8 mice
each. When mice developed palpable tumors (approximate tumor
size of 20 mm3), they were treated with either the vehicle,
dimethylsufoxide (DMSO), or RA (2.5 mg/kg body weight) by
intraperitoneal (i.p.) injection five times a week, up to six weeks.
Tumors size was measured with a digital caliper twice a week, and
tumor volumes were calculated as described [43]. Mice were
monitored and weighed weekly. At the end of the sixth week, mice
were euthanized. Data were analyzed by one-way ANOVA,
followed by multiple comparison tests (STATISTICA program,
Tulsa, OK, USA). All statistical tests were two-sided. The level of
significance was set at p,0.05.
Three tumors (right side) randomly selected from each group of
mice were removed and cut in half. One half was snap-frozen in
liquid nitrogen and used for evaluating cyclin D1 transcription by
quantitative real time RT-PCR. The other half was fixed in 10%
neutral-buffered formalin and used for immunohistochemical
analysis of the Ki67, a parameter of cell proliferation. Fixed
tissues embedded in paraffin were sectioned. 5 mm-sections were
reacted with either a rabbit anti-Ki67 human antibody (Dako,
Carpinteria, CA) or horse serum as a control, followed by
a biotinylated horse anti-rabbit antibody (BioGenex, San Ramon,
CA), and visualized by using streptavidin horseradish peroxidase/
diaminobenzidine. Sections were counterstained with hematoxylin
and mounted. Ki67-positive cells were quantified as described
[44]. The differences between two-pair samples were analyzed by
the two-tailed Student’s t test.
Quantitative real-time RT-PCR
Total RNA isolated by Trizol (Invitrogen) followed by DNase I
(Qiagen) treatment, and retrotranscribed into cDNA with
a SuperScript First-Strand Synthesis System (Invitrogen) was
amplified with iQ SYBR Green Supermix kit (BioRad, Hercules,
CA) in combination with specific primers using a MyiQ Real-
Time PCR Detection System (BioRad). The primer sequences
were as follows: cyclin D1 (sense: 59-CTG TGC TGC GAA GTG
GAA ACC AT-39; antisense: 59-TGG AGT TGT CGG TGT
AGA TGC ACA-39), nSMase (sense: 59-CAA CAA GTG TAA
CGA CGA TGC C-39; antisense: 59-CGA TTC TTT GGT CCT
GAG GTG T-39), SK1 (sense: 59-CTG GCA GCT TCC TTG
AAC CAT-39; antisense: 59-TGT GCA GAG ACA GCA GGT
TCA-39); LCB1 (sense, 59-TTA ACT CAG GCG CGC TAC
TTG-39 and antisense, 59-TGT TGT TCC ACC GTG ACC A-
39); LCB2 (sense, 59-GCC ACC CCA ATT ATT GAG TCC-39
and antisense, 59-TGC AAT AGG TCC CCA ACT TCA-39);
SK2 (sense, 59-CCA GTG TTG GAG AGC TGA AGG T-39 and
antisense, 59-GTC CAT TCA TCT GCT GGT CCT C-39);
aSMase (sense, 59-TGG CTC TAT GAA GCG ATG GC-39 and
antisense, 59-TTG AGA GAG ATG AGG CGG AGA C-39); S1P
phosphatase (sense, 59-TGA GTA CAG CAT GCC CTC CA-39
and antisense, 59-GGC AAA CTA GAG AAC ACC AGC A-39);
S1P lyase (sense, 59-GAG CAC CCA TTT GAT TTC CG-39 and
antisense, 59-CAC CAA TGA TGA GCC TTT TGG-39); GAPDH
(sense: 59-GAA GGT GAA GGT CGG AGT C-39; antisense: 59-
GAA GAT GGT GAT GGG ATT TC-39). The level of the
different transcripts was normalized to the level of the GAPDH
transcript, and quantified by the threshold cycle Ct method.
Diacylglycerolkinase (DGK) assay
Lipids were extracted according to the method of Bligh and Dyer
[45]. CER was quantitated with the DGK assay [46]. Briefly,
30 nmol of lipids, quantitated as inorganic phosphate [47], were
incubated in the presence of 20 ml b-octylglucoside/dioleoylpho-
sphatidylglycerol micelles [48], 2 mM dithiothreitol, 6 mg of
Escherichia coli DGK (Calbiochem), 1 mM ATP, 1.3 mCi of
[c32-P] ATP (3 Ci/mmol) (Perkin Elmer Life Sciences Inc., Boston,
MA) in a final volume of 100 ml at 25uC for 45 minutes.
Radioactive lipids were separated, along with reference lipid
standards (Avanti Polar Lipids, Alabaster, AL), by thin layer
chromatography (TLC), with chloroform/acetone/methanol/
acetic acid/water (10/4/3/2/1, by vol). Radioactive CER
phosphate spots were visualized by autoradiography, scraped,
and counted by liquid scintillation.
Quantitation of de-novo generated ceramide by [3H]
palmitate labeling
66105 cells were labeled with 4 mCi of [9,10(n)-3H] palmitate (55
Ci/mmol) (Amersham Biosciences Italy, Italy) in the presence of
either RA (1 mM) or ethanol (vehicle) at 37uC for 10 h. Lipids,
extracted as described previously, were subjected to mild alkaline
hydrolysis (0.1 N NaOH in methanol, at 55uC for 1 h), 48 h-dialysis
against distilled water, lyophilized, resuspended in 50 ml chloro-
form/methanol (2/1, by vol) and separated along with reference
standards by TLC using chloroform/methanol/2N NH4OH (40/
7.5/1, by vol). Radioactive CER spots were visualized by
fluorography, scraped, and counted by liquid scintillation.
Quantitation of SMase-generated ceramide by [3H]
sphingosine labeling
66105 cells were labeled with 0.4 mCi [3-3H]D-erythro-sphingo-
sine (23 Ci/mmoles) (Perkin Elmer) at 37uC for 72 h, before
adding RA (1 mM) or ethanol (vehicle) for additional 72 h. Lipids
were extracted as described above. Radioactive lipids and
reference standards were resolved by TLC using either chloro-
form/methanol/2N NH4OH (40/7.5/1, by vol) for CER
separation or chloroform/methanol/formic acid/water (65/25/
8.9/1.1, by vol) for sphingomyelin separation. Radioactive CER
and sphingomyelin spots, visualized by fluorography and recog-
nized by comparison with reference standards, were scraped and
counted by liquid scintillation.
Acid sphingomyelinase (aSMase) activity assay
aSMase activity was determined essentially as described [49].
Briefly, cells were lysed by three freeze-thawing cycles in 200 ml of
a lysis buffer containing 50 mM Tris-HCl (pH 7.4), 1 mM EDTA,
0.1% Triton X-100, 5 mM dithiothreitol, 1 mM phenylmethyl-
sulfonyl fluoride, and 2 ml of a protease inhibitor cocktail (Sigma).
The lysate was centrifuged at 10006g for 15 min. The
supernatant was collected, and protein content determined by
Comassie Plus assay (Pierce Biotechnology, Inc, Rockford, IL).
The protein concentration was adjusted at 1 mg/ml with lysis
buffer. 50 mg proteins were added to 50 ml solution, which was
previously sonicated for 30 sec, containing 200 mM sodium
acetate, pH 5.0, 0.1% Triton X-100, 0.5 mCi [N-methyl-14C]
sphingomyelin (54.0 mCi/mmol) (Amersham Biosciences) and
100 mM sphingomyelin (Sigma) and incubated at 37uC for
60 min. The reaction was stopped by adding 1.5 ml chloro-
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form/methanol (2/1, by vol) and 0.2 ml distilled water. Phases
were separated by centrifugation at 20006g for 5 min. Upper
aqueous phase aliquots were counted by liquid scintillation.
Neutral sphingomyelinase (nSMase) activity assay
nSMase activity was determined essentially as described [49].
Briefly, 96106 cells were lysed by three freeze-thawing cycles in
200 ml of a lysis buffer containing 50 mM Tris-HCl (pH 7.4),
1 mM EDTA, 0.1% Triton X-100, 5 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, and 2 ml of a protease inhibitor
cocktail (Sigma). The cell lysate was centrifuged at 10006g for
15 min. The supernatant was collected for protein content
determination by the Comassie Plus assay (Pierce Biotechnology,
Inc.). The protein concentration was adjusted to 1 mg/ml with the
lysis buffer. 50 mg proteins were added to 50 ml of a solution,
which was previously sonicated for 30 sec, containing 100 mM
Tris-HCl (pH 7.4), 10 mM MgCl2, 0.2% Triton X-100, 10 mM
dithiothreitol, 0.5 mCi [N-methyl-14C] sphingomyelin (54 mCi/
mmol) (Amersham Biosciences, Buckingamshire, UK), and
100 mM sphingomyelin (Sigma), and incubated for 60 min at
37uC. The reaction was stopped by adding 1.5 ml chloroform/
methanol (2/1, by vol) and 0.2 ml distilled water. Phases were
separated by centrifugation at 20006g for 5 min. Upper aqueous
phase aliquots were counted by liquid scintillation.
Serine palmitoyltransferase (SPT) activity assay
The activity of SPT was determined essentially as described [50].
Briefly, 16107cells were lysed by three freeze-thawing cycles in
300 ml of a lysis buffer containing 25 mM Hepes (pH 7.4), 5 mM
EGTA, 50 mM NaF, 3 ml of a protease inhibitor cocktail (Sigma).
The cell lysate was centrifuged at 10006g for 15 min. The
supernatant was collected and protein content determined by
Comassie Plus assay (Pierce Biotechnology, Inc.). The protein
concentration was adjusted to 5 mg/ml with lysis buffer. 200 mg
proteins were added to 160 ml solution containing 100 mM Hepes
(pH 8.3), 2.5 mM EDTA, pH 7.4, 50 mM pyridoxalphosphate,
5 mM dithiothreitol, 1 mM L-serine (200 ml final volume). After
a pre-incubation at 37uC for 5 min, 1 mCi L-[3H(G)]serine (26.0 Ci/
mmol) (Perkin Elmer) and 20 ml 2 mM palmitoyl CoA were added.
Incubation was allowed to proceed for 20 min at 37uC and stopped
by adding 1.5 ml of chloroform/methanol (1/2, by vol), 25 mg D-
erythro-sphingosine (Avanti Polar), 1.5 ml chloroform and 2 ml 0.5
N NH4OH. Phases were separated by centrifugation at 20006g for
5 min. The lower organic phase was washed twice with 2 ml distilled
water. Aliquots were dried and counted by liquid scintillation.
Sphingosine kinase (SK) activity assay
SK activity was determined essentially as described [51]. Briefly,
96106 cells were lysed by three freeze-thawing cycles in 200 ml of
a lysis buffer containing 20 mM Tris-HCl (pH 7.4), 10% glycerol,
1 mM b-mercaptoethanol, 1 mM EDTA, 1 mM sodium ortho-
vanadate, 15 mM NaF, 40 mM b-glycerophosphate, 0.5 mM
deoxypiridoxine, 0.1% Triton X-100, 2 ml of a protease inhibitor
cocktail (Sigma). The cell lysate was centrifuged at 13,0006g for
30 min. The supernatant was collected for protein content
determination by the Comassie Plus assay (Pierce Biotechnology,
Inc.). The protein concentration was adjusted to 1 mg/ml by
adding lysis buffer. 100 mg (100 ml) protein were added to 10 ml of
1 mM D-erythro-sphingosine (Avanti Polar) dissolved in 0.1%
Triton X-100 and 10 ml of a solution containing 10 mCi [c32P]
ATP (3 Ci/mmol) (Perkin Elmer), 20 mM MgCl2, 2 mM ATP,
and incubated at 37uC for 30 min. The reaction was stopped by
adding 20 ml 1 N HCl and 0.8 ml chloroform/methanol/37%
HCl (100/200/1, by vol ) followed after 10 min by the addition of
250 ml chloroform and 250 ml 2 M KCl. Phases were separated by
centrifugation at 20006g for 5 min. The lower organic phase was
collected, dried and redissolved in 50 ml of chloroform/methanol/
37% HCl (100/200/0.2, by vol). Radioactive lipids were resolved
by TLC using n-butanol/acetic acid/water (3/1/1, by vol).
Labeled S1P, visualized by autoradiography and recognized by
comparison with a reference standard, was scraped and counted
by liquid scintillation.
Intracellular S1P assay
Intracellular S1P was determined essentially as described [52].
66105 cells were labeled with 0.8 mCi of [3-3H]D-erythro-
sphingosine (23 Ci/mmoles) (Perkin Elmer) and 50 pmoles of
sphingosine (Avanti Polar) in 100 ml DMEM, for 2 h at 37uC.
Lipids were extracted by addition of 1.9 ml chloroform/
methanol/37% HCl (100/200/1, by vol), 625 ml chloroform and
625 ml 2 M KCl. Phases were separated by centrifugation at
20006g for 5 min. The lower organic phase was collected, dried,
and dissolved in 30 ml of chloroform/methanol (2/1, by vol).
Radioactive lipids were resolved by TLC using n-butanol/acetic
acid/water (3/1/1, by vol). Labeled S1P, visualized by fluorog-
raphy and recognized by comparison with a reference standard,
was scraped and counted by liquid scintillation.
Statistical analysis
Unless specifically stated, data represent the mean of three
independent experiments6standard deviation (SD). The signifi-
cance of differences between groups was obtained by the Student’s
t-test. In the Figures one asterisk correspond to p,0.05, two
asterisks to p,0.01 and three asterisks to p,0.001.
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